|Bid||169.55 x 100|
|Ask||171.30 x 500|
|Day's Range||168.89 - 170.49|
|52 Week Range||138.83 - 191.10|
|PE Ratio (TTM)||15.47|
|Earnings Date||Jan 31, 2018 - Feb 5, 2018|
|Forward Dividend & Yield||4.60 (2.71%)|
|1y Target Est||189.86|
GE isn’t the only household name I’m worried about. There is another popular dividend stock showing some very similar signs.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & Johnson (PFE-US, BMY-US, GSK-US, CELG-US, GILD-US, ABBV-US, BIIB-US, ALXN-US, RHHVF-US ... Read more (Read more...)
THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ -- Amgen (AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients. The AutoTouch™ reusable autoinjector is used with ENBREL Mini™ single-dose prefilled cartridges (50 mg/mL) that utilize a new drug formulation of ENBREL that was associated with substantially significant lower mean injection site pain than the current formulation.
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last month, growth of ETFs holding AMGN is favorable, with net inflows of $17.19 billion.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
THOUSAND OAKS, Calif., Nov. 13, 2017 /PRNewswire/ -- Amgen (AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the addition of Repatha to statin therapy improved clinical outcomes with significant reduction of cardiovascular (CV) events, such as heart attack (also called myocardial infarction or MI) and stroke, in high-risk patients with peripheral artery disease (PAD), and in patients with a history of heart attack. The analyses, including two accepted for late-breaker scientific sessions, were presented at the American Heart Association (AHA) Scientific Sessions 2017.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amgen, Inc. Here are 5 ETFs with the largest exposure to AMGN-US. Comparing the performance and risk of Amgen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Shares of Amgen Inc (NASDAQ:AMGN) will begin trading ex-dividend in 3 days. To qualify for the dividend check of $1.15 per share, investors must have owned the shares prior toRead More...
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). The positive CHMP opinion was based on five studies evaluating the safety and efficacy of Nplate in children with ITP, including four completed studies (a Phase 3, a Phase 1/2 placebo-controlled study, and two long-term safety and efficacy studies) and one ongoing long-term safety and efficacy study. "Children with ITP are at risk for serious bleeding events due to low platelet counts, and currently, limited therapeutic options are available to treat this rare disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab).
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current dealmaking environment on Wall Street, as M&A and IPO activity heat up. Is it the sign of a market top, as some analysts are warning?